Copy of Press Release Issued by the Company,
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemkart India Limited has issued a press release addressing a Directorate of Revenue Intelligence (DRI) investigation into the classification and valuation of select imported chemical consignments — Instantized BCAA, L-Leucine, L-Isoleucine, and Valine powders — over the last five years. These products contributed an average of only ~2.8% to the company's annual turnover, ranging from 1.76% to 5.34% across FY22–FY26 (till Dec 15, 2025). The total differential customs duty liability for the period has been assessed at approximately INR 15.72 crores, of which INR 12.78 crores has already been paid and the remaining INR 2.94 crores will be settled within seven days. The company has grown its annual turnover from INR 86.97 crores in FY22 to INR 203 crores in FY25, with INR 145 crores already recorded in FY26 (till Dec 15). Management states the matter will not have a material adverse impact on operations, financial stability, or growth plans, though short-term liquidity tightness is acknowledged.
Shareholders should note a one-time customs duty outflow of ~INR 15.72 crores that may pressure short-term liquidity, but the investigation relates to a small product line (~2.8% of revenue) and the company has already paid ~81% of the liability. The proactive disclosure and management's assurance of no material impact on business fundamentals should help limit negative sentiment, though the stock may still face some volatility in the near term until the matter is fully closed.